Glenmark's monoclonal antibody enters human trials stage
With this, Glenmark now has three monoclonal antibodies in clinical development
BS B2B Bureau B2B Connect | Mumbai
)
OX40 is a very well validated target with the potential to treat a wide array of autoimmune diseases. However, discovering antibodies that inhibit OX40 and do not have agonistic properties, which would lead to unwanted side effects, has proven very difficult and based on Glenmark’s data GBR 830 is devoid of any agonistic properties.
GBR 830 targets auto-reactive T cells. This cell type drives the pathology in most autoimmune diseases and including, but not limited to illnesses such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and lupus.
Also Read
Dr Michael Buschle, President of Biologics and Chief Scientific Officer, Glenmark Pharmaceuticals Ltd, said, “With GBR 830, Glenmark has succeeded in generating a truly antagonistic OX40 antibody. This was a very difficult program but our persistence ultimately paid off.”
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jul 04 2014 | 5:30 PM IST